Martine Jandrot-Perrus

Martine Jandrot-Perrus has devoted her research to understanding the mechanisms leading to the formation of a clot (physiological) / thrombus (pathological), with a particular interest for the processes taking place at the interface between the plasma (coagulation), the cells (platelets) and fibrin (fibrinolysis). She has largely contributed to the characterization of a major platelet receptor, glycoprotein VI (GPVI) with as major outcome the proposal that thrombosis is not a simple inappropriate haemostatic response but has specificities representing pharmacological targets to design antithrombotic molecules without haemorrhagic risk. Her work, having shown the remarkable inhibitory effect of the antibody fragment Fab 9O12 on GPVI functions, led to the development of therapeutic humanized Fab, ACT017. Data from preclinical studies and from first in human administration confirm that ACT017 combines safety (absence of bleeding) and antithrombotic efficiency.